Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.

Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, Shi CX, Stein CK, Bergsagel M, Chau B, Wheeler ML, Bezman N, Wang F, Strop P, Bergsagel PL, Chesi M
Blood Cancer Discov. 2021 Jul;2(4):354-369. doi: 10.1158/2643-3230.BCD-21-0038. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.